The immune escape in melanoma: role of the impaired dendritic cell function

References

• Caini S, Gandini S, Sera F, et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. Eur J Cancer 2009;45:3054-63
   PubMedGoogle Scholar
• Kukreja A, Hutchinson A, Dhodapkar K, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006;203:1859-65
   PubMed Web of Science ®Google Scholar
• Della Bella S, Nicola S, Brambilla L, et al. Quantitative and functional defects of dendritic cells in classic kaposi’s sarcoma. Clin Immunol 2006;119:317-29
   PubMedGoogle Scholar
• Cormier JN, Hijazi YM, Abati A, et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998;75:517-24
   PubMed Web of Science ®Google Scholar
• Andersen MH, Gehl J, Reker S, et al. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 2003;13:449-59
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8
   PubMed Web of Science ®Google Scholar
• Urosevic M, Braun B, Willers J, et al. Expression of melanoma-associated antigens in melanoma cell cultures. Exp Dermatol 2005;14:491-7
   PubMedGoogle Scholar
• Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Ann Rev Immunol 2006;24:175-208
   PubMed Web of Science ®Google Scholar
• Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev 2010;234:45-54
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52
   PubMed Web of Science ®Google Scholar
• Shurin MR, Shurin GV, Lokshin A, et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 2006;25:333-56
   PubMed Web of Science ®Google Scholar
• Jacobs JFM, Nierkens S, Figdor CG, et al. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012;13:e32-42
   PubMed Web of Science ®Google Scholar
• McCarter MD, Baumgartner J, Escobar GA, et al. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol 2007;10:2854-60
   Google Scholar
• Polak ME, Borthwick NJ, Gabriel FG, et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 2007;96:1879-87
   PubMed Web of Science ®Google Scholar
• Biollaz G, Bernasconi L, Cretton C, et al. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. Eur J Immunol 2009;39:1323-33
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010;107:4275-80
   PubMed Web of Science ®Google Scholar
• Alexandrescu DT, Ichim TE, Riordan NH, et al. Immunotherapy for melanoma: current status and perspectives. J Immunother 2010;33:570-90
   PubMedGoogle Scholar
• Umansky V. New strategies for melanoma immunotherapy. How to overcome immunosuppression in the tumor microenvironment. Oncoimmunology 2012;5:765-7
   Google Scholar
• Engell-Noerregaard L, Hansen TH, Andersen MH, et al. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009;58:1-14
   PubMed Web of Science ®Google Scholar
• Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003;170:1257-66
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Tucci M, Stucci S, Strippoli S, et al. Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression? Oncologist 2011;11:1040-8
   Google Scholar
• Dhodapkar M, Dhodapkar K, Palucka AK. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ 2008;15:39-50
   PubMed Web of Science ®Google Scholar
• Fujimura T, Kambayashi Y, Aiba S. Crosstalk between regulatory T-cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth. Oncoimmunology 2012;1:1433-4
   PubMed Web of Science ®Google Scholar
• Mellman I. Dendritic cells: master regulators of the immune response. Cancer Immunol Res 2013;1:145
   PubMed Web of Science ®Google Scholar
• Nouri-Shirazi M, Bancherau J, Bell D, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000;165:3797-803
   PubMed Web of Science ®Google Scholar
• Collin M, Mcgover N, Haniffa M. Human dendritic cell subsets. Immunology 2013;140:22-30
   PubMed Web of Science ®Google Scholar
• Tucci M, Quatraro C, Lombardi L, et al. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum 2008;58:251-62
   PubMed Web of Science ®Google Scholar
• Spel L, Boelens JJ, Nierkens S, Boes M. Antitumor immune responses mediated by dendritic cells: how signals derived from dying cancer cells drive antigen cross-presentation. Oncoimmunology 2013;2:e26403
   Google Scholar
• Palucka K, Banchereau J, Mellman I. Designing vaccines based onbiology of human dendritic cell subsets. Immunity 2010;33:464-78
   PubMed Web of Science ®Google Scholar
• Mellman I, Steinman RM. Dendritic cells: specialised and regulated antigen processing machines. Cell 2001;106:255-8
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001;106:263-6
   PubMed Web of Science ®Google Scholar
• Failli A, Legitimo A, Orsini G, et al. Numerical defect of circulating dendritic cell subsets and defective dendritic cell generation from monocytes of patients with advanced melanoma. Cancer Lett 2013;337:184-92
   Google Scholar
• Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003;200:255-68
   Google Scholar
• Gerner MY, Mescher MF. Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells. J Immunol 2009;182:2726-37
   Google Scholar
• Ataera H, Hyde E, Price KM, et al. Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. PLoS One 2011;6:e17515
   Google Scholar
• Charles J, Di Domizio J, Salameire D, et al. Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Dermatol 2010;130:1646-56
   PubMedGoogle Scholar
• Ito M, Minamiya Y, Kawai H, et al. Tumor-derived TGFβ-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol 2006;176:5637-43
   PubMed Web of Science ®Google Scholar
• Ladanyi A, Kiss J, Somlai B, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007;56:1459-69
   PubMed Web of Science ®Google Scholar
• Klarquist JS, Janssen EM. Melanoma-infiltrating dendritic cells. Limitations and opportunities of mouse models. Oncoimmunology 2012;9:1584-93
   Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74
   PubMed Web of Science ®Google Scholar
• Fujimura T, Mahnke K, Enk AH. Myeloid derived suppressor cells and their role in tolerance induction in cancer. J Dermatol Sci 2010;59:1-6
   PubMed Web of Science ®Google Scholar
• Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007;13:5243-8
   PubMed Web of Science ®Google Scholar
• Tanikawa T, Wilke CM, Kryczek I, et al. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res 2012;72:420-9
   PubMed Web of Science ®Google Scholar
• Fujimura T, Kambayashi Y, Aiba S. Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth. Oncoimmunology 2012;1:1433-4
   PubMed Web of Science ®Google Scholar
• Jordan KR, Amaria RN, Ramirez O, et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunopathol 2013;62:1711-22
   PubMed Web of Science ®Google Scholar
• Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol 2011;2011:430394
   PubMed Web of Science ®Google Scholar
• Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory T cells in cancer. Adv Cancer Res 2010;107:57-117
   PubMed Web of Science ®Google Scholar
• Baumgartner J, Wilson C, Palmer B, et al. Melanoma Induces Immunosuppression by Upregulating FOXP3+ Regulatory T Cells. J Surg Res 2007;141:72-7
   PubMed Web of Science ®Google Scholar
• Apostolou I, Verginis P, Kretschmer K, et al. Peripherally induced Treg: mode, stability and role in specific tolerance. J Clin Immunol 2008;28:619-24
   PubMed Web of Science ®Google Scholar
• Attia P, maker AV, Haworth LR, et al. Inability of a fusion protein of IL-2 and diphtheria toxin to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005;28:582-92
   PubMed Web of Science ®Google Scholar
• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51
   PubMed Web of Science ®Google Scholar
• Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54
   PubMed Web of Science ®Google Scholar
• Hodgea DR, Hurtb EM, Farrar WL, The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005;41:2502-12
   PubMedGoogle Scholar
• Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002;2:410-16
   PubMedGoogle Scholar
• Kortylewski M, Jove E, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005;24:315-27
   PubMed Web of Science ®Google Scholar
• Borin Scutti JA, Matsuo AL, Valenca Pereira F, et al. Role of SOCS-1 gene on melanoma cell growth and tumor development. Transl Oncol 2011;4:101-9
   PubMedGoogle Scholar
• Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002;21:7001-10
   PubMed Web of Science ®Google Scholar
• Pansky A, Hildebrand P, Fasler-Kan E, et al. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 2000;85:720-5
   PubMed Web of Science ®Google Scholar
• Wong LH, Krauer KG, Hatzinisiriou I, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997;272:79-85
   Google Scholar
• Li Z, Metze D, Nashan D, et al. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 2004;123:737-45
   PubMed Web of Science ®Google Scholar
• Lee I, Fox PS, Ferguson SD, et al. The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget 2012;3:336-44
   PubMedGoogle Scholar
• Niu G, Heller R, Catlett-Falcone R, et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999;59:5059-63
   PubMed Web of Science ®Google Scholar
• Homsi J, Cubitt CL, Zhang S, et al. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res 2009;19:167-75
   PubMed Web of Science ®Google Scholar
• Postow MA, Harding J, Wolchok JD. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 2012;18:153-9
   PubMed Web of Science ®Google Scholar
• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;22:237-51
   Google Scholar
• Holmgaard RB, Zamarin D, Munn DH, et al. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 2013;210:1389-402
   PubMed Web of Science ®Google Scholar
• Shirota H, Klinman DM. Use of CpG oligonucleotides for cancer immunotherapy and their effect on immunity in the tumor microenvironment. Immunotherapy 2013;5:787-9
   PubMedGoogle Scholar
• Vicari AP, Chiodoni C, Vaure C, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002;196:541-9
   PubMed Web of Science ®Google Scholar
• Palucka K, Bancherau J. Dendritic cell-based therapeutic cancer vaccines. Immunity 2013;39:38-48
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase-III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-70
   PubMed Web of Science ®Google Scholar
• Agrawai S, Reemtsma K, Bagiella E, et al. Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenity of mouse melanoma. Cell Immunol 2004;228:130-7
   PubMedGoogle Scholar
• Benencia F, Sprague L, McGinty J, et al. Dendritic cells, the tumor microenvironment an the challenges for an effective antitumor vaccination. J Biomed Biotechnol 2012;2012:425476
   PubMedGoogle Scholar
• Kantoff PW, Higano CS, Shore MD, et al. Sipuleucel-T immunotheraphy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
   PubMed Web of Science ®Google Scholar
• Tel J, Aarntzen EHJG, Baba T, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013;73:1063-75
   PubMed Web of Science ®Google Scholar
• Fidgor CL, de Vries IJM, Lesterhuis WJ, Melief CJM. Dendritic cell immunotheraphy: mapping the way. Nat Med 2004;10:475-80
   PubMedGoogle Scholar
• Orabona C, Grohmann U, Belladonna ML, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 2004;5:1134-42
   PubMed Web of Science ®Google Scholar
• Laurent S, Carrega P, Saverino D, et al. CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum Immunol 2010;71:934-41
   PubMed Web of Science ®Google Scholar
• Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immunol 2013;13:5
   PubMedGoogle Scholar
• Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013;1:32-42
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013;210:1695-710
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;30:2507-16
   Google Scholar
• Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014;12:116
   PubMed Web of Science ®Google Scholar
• Merelli B, Massi D, Cattaneo L, Mandalà M. Targeting the PD1/PDL1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014;89:140-65
   PubMed Web of Science ®Google Scholar